Renaissance Capital logo

ICPT News

Biotech IPOs Focused on NASH

After years of disappointing clinical trials for nonalcoholic steatohepatitis (NASH), an often fatal liver disease associated with obesity and diabetes, there are a number of promising late-stage clinical trials underway, including two being conducted by pending...read more

Liver disease biotech Lumena Pharmaceuticals files for a $75 million IPO

Lumena Pharmaceuticals, a clinical-stage biotech developing candidates for rare liver diseases, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering. The San Diego, CA-based company, which was founded in 2011, plans to list on...read more

Nine US IPO pricings cap busiest period since early 2011

Led by the blockbuster Workday (WDAY) and Realogy (RLGY) IPOs, all nine companies on the US IPO calendar priced this week, closing off a very active period in the...read more

Shutterstock prices IPO at $17, above the range

Shutterstock (SSTK), an online marketplace for royalty-free images and videos, raised $77 million by offering 4.5 million shares at $17, above the range of $13 to $15. Shutterstock plans to list on the NYSE under the symbol SSTK. Morgan Stanley, Deutsche Bank...read more